Alembic Limited
NSE: ALEMBICLTD BSE: ALEMBICLTD
NSE
89.61
0.63 (0.71%)
Prev Close
88.98
Open Price
89.1
Volume
318,577
Today Low / High
87.7 / 91.65
52 WK Low / High
78.1 / 169
Range
85 - 94
BSE
90.68
1.64 (1.84%)
Prev Close
89.04
Open Price
88.66
Volume
47,943
Today Low / High
87.56 / 91.55
52 WK Low / High
78.2 / 169
Range
86 - 95
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 89.61 (target range: 85 - 94), reflecting a change of 0.63 (0.70802%). On the BSE, it is listed at 90.68 (target range: 86 - 95), showing a change of 1.64 (1.84187%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.
04 Mar
89.10
1.26%
03 Mar
91.99
-3.27%
28 Feb
94.00
-3.11%
27 Feb
98.69
-3.50%
25 Feb
98.70
-0.14%
24 Feb
99.05
0.70%
21 Feb
102.67
-2.05%
20 Feb
100.35
2.47%
19 Feb
96.59
4.13%
18 Feb
101.10
-4.93%
17 Feb
100.39
-0.42%
14 Feb
104.14
-4.28%
13 Feb
105.00
-1.31%
12 Feb
106.00
-1.27%
11 Feb
111.00
-4.85%
10 Feb
115.00
-2.90%
07 Feb
116.50
-3.15%
06 Feb
115.10
1.09%
05 Feb
112.50
0.63%
04 Feb
113.60
-1.76%
Alembic Limited Graph
Alembic Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking Target Price for Alembic Limited T1, T2, T3, for both Bullish or Bearish. For Bullish T1, T2, T3 and for Bearish T1, T2, T3. The stock current price is 90, with potential price targets ranging from T1, T2, T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 90.68 | 91.59 | 82.43 - 100.75 |
| 92.49 | 73.99 - 110.99 | ||
| 93.40 | 65.38 - 121.42 | ||
| Bearish Scenario | 90.68 | 89.77 | 80.80 - 98.75 |
| 88.87 | 71.09 - 106.64 | ||
| 87.96 | 61.57 - 114.35 |
Overview of Alembic Limited
ISIN
INE426A01027
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
594,447
Market Cap
22,984,556,730
Last Dividend
2.4
Official Website
IPO Date
2002-07-01
DCF Diff
206.88
DCF
-103
Financial Ratios Every Investor Needs
Stock Dividend of ALEMBICLTD
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2024-08-05 | August 05, 24 | 2.4 | 2.4 | 2024-08-05 | 2024-09-11 | |
| 2023-08-03 | August 03, 23 | 2.2 | 2.2 | 2023-08-03 | 2023-09-09 | |
| 2022-09-12 | September 12, 22 | 1.8 | 1.8 | 2022-09-13 | 2022-09-23 | |
| 2021-07-29 | July 29, 21 | 0.2 | 0.2 | 2021-07-30 | 2021-08-10 | |
| 2020-07-29 | July 29, 20 | 0.6 | 0.6 | 2020-07-30 | 2020-08-11 | 2020-05-25 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 157.49 Cr | 59.88 Cr | 97.61 Cr | 0.6198 | 0.10 Cr | 6.70 Cr | 76.78 Cr | 268.62 Cr | 10.46 | 105.50 Cr | 1.7057 |
| 2023-03-31 | 127.24 Cr | 41.12 Cr | 86.12 Cr | 0.6768 | 0.66 Cr | 5.51 Cr | 33.61 Cr | 190.65 Cr | 7.42 | 40.33 Cr | 1.4983 |
| 2022-03-31 | 71.37 Cr | 31.07 Cr | 40.30 Cr | 0.5647 | 1.03 Cr | 6.36 Cr | 9.07 Cr | 222.06 Cr | 8.65 | 13.93 Cr | 3.1114 |
| 2021-03-31 | 67.84 Cr | 28.56 Cr | 39.27 Cr | 0.5789 | 0.39 Cr | 3.64 Cr | 7.13 Cr | 342.84 Cr | 13.35 | 11.07 Cr | 5.0539 |
| 2020-03-31 | 67.26 Cr | 38.60 Cr | 28.66 Cr | 0.4261 | 0.15 Cr | 4.83 Cr | 0.05 Cr | 329.12 Cr | 12.82 | 96.39 Cr | 4.8936 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 1.26 Cr | 2,328.77 Cr | 143.21 Cr | 2,185.5645 Cr | 9.15 Cr | 7.89 Cr | 92.60 Cr | 131.64 Cr | 0.00 Cr | 0.00 Cr | 1,774.71 Cr | 90.3159 Cr |
| 2023-03-31 | 0.93 Cr | 2,204.58 Cr | 126.54 Cr | 2,078.0400 Cr | 0.00 Cr | -0.93 Cr | 88.61 Cr | 131.96 Cr | 34.35 Cr | 1.81 Cr | 1,708.20 Cr | 83.8100 Cr |
| 2022-03-31 | 1.17 Cr | 2,631.95 Cr | 135.37 Cr | 2,496.5833 Cr | 0.00 Cr | -1.17 Cr | 86.87 Cr | 133.69 Cr | 26.62 Cr | 2.02 Cr | 2,182.05 Cr | 67.7648 Cr |
| 2021-03-31 | 5.89 Cr | 2,408.96 Cr | 111.93 Cr | 2,297.0281 Cr | 0.28 Cr | -5.61 Cr | 54.28 Cr | 139.53 Cr | 36.60 Cr | 1.94 Cr | 2,030.59 Cr | 59.4153 Cr |
| 2020-03-31 | 58.30 Cr | 1,470.72 Cr | 52.68 Cr | 1,418.0418 Cr | 0.03 Cr | -58.27 Cr | 35.41 Cr | 133.71 Cr | 28.95 Cr | 1.92 Cr | 1,078.88 Cr | 45.7974 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 22.6865 Cr | 25.8363 Cr | -48.1936 Cr | -33.6034 Cr | 0.3291 Cr | 1.2609 Cr | -56.2899 Cr | 102.6862 Cr | 9.1490 Cr | -56.2340 Cr | -3.9900 Cr |
| 2023-03-31 | 38.8500 Cr | 7.3000 Cr | -46.3900 Cr | 13.0300 Cr | -0.2400 Cr | 0.9300 Cr | -25.8200 Cr | 86.8000 Cr | 0.0000 Cr | -45.9229 Cr | -1.7400 Cr |
| 2022-03-31 | -17.7469 Cr | 18.8478 Cr | -5.8165 Cr | -53.5601 Cr | -4.7157 Cr | 1.1714 Cr | -35.8132 Cr | 97.8574 Cr | -0.2766 Cr | -5.1508 Cr | -32.5884 Cr |
| 2021-03-31 | -2.1817 Cr | -34.7375 Cr | -15.3620 Cr | -49.6370 Cr | -52.2813 Cr | 6.5737 Cr | -47.4553 Cr | 17.0412 Cr | 0.0000 Cr | -15.2767 Cr | -18.8683 Cr |
| 2020-03-31 | 6.1729 Cr | 56.7225 Cr | -6.0456 Cr | -16.1813 Cr | 56.8497 Cr | 58.8550 Cr | -22.3542 Cr | 93.1652 Cr | 0.0000 Cr | -6.1211 Cr | -0.0857 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | 57.92 Cr | 17.00 Cr | 40.92 Cr | 0.7065 | 0.00 Cr | 65.39 Cr | 2.55 | 30.77 Cr | 1.1290 |
| 2024-09-30 | 52.91 Cr | 18.71 Cr | 34.20 Cr | 0.6464 | 0.00 Cr | 121.02 Cr | 4.71 | 85.18 Cr | 2.2873 |
| 2024-06-30 | 50.78 Cr | 26.31 Cr | 24.47 Cr | 0.4819 | 26.97 Cr | 55.82 Cr | 2.17 | 20.40 Cr | 1.0993 |
| 2024-03-31 | 49.04 Cr | 18.98 Cr | 30.06 Cr | 0.6130 | 22.67 Cr | 72.15 Cr | 2.81 | 26.19 Cr | 1.4712 |
| 2023-12-31 | 39.32 Cr | 14.13 Cr | 25.19 Cr | 0.6406 | 11.25 Cr | 61.42 Cr | 2.39 | 13.90 Cr | 1.5621 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2024-09-30 | 1.75 Cr | 44.01 Cr | 45.76 Cr | 0.00 Cr | 97.05 Cr | 199.72 Cr | 131.37 Cr | 2,440.96 Cr | 194.53 Cr |
| 2024-06-30 | 0.00 Cr | 0.00 Cr | 12.86 Cr | 0.00 Cr | 0.00 Cr | 12.86 Cr | 0.00 Cr | 0.00 Cr | -2,185.56 Cr |
| 2024-03-31 | 2.46 Cr | 92.60 Cr | 95.06 Cr | 22.03 Cr | 11.34 Cr | 137.39 Cr | 131.64 Cr | 2,328.77 Cr | 143.21 Cr |
| 2023-12-31 | -4.63 Cr | 9.26 Cr | 4.63 Cr | 0.00 Cr | 0.00 Cr | 4.63 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-09-30 | 1.88 Cr | 13.55 Cr | 15.43 Cr | 21.52 Cr | 86.54 Cr | 139.62 Cr | 131.71 Cr | 2,269.72 Cr | 150.06 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2024-06-30 | 55.82 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-03-31 | 72.15 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-12-31 | 61.42 Cr | 5.32 Cr | 0.00 Cr | 0.00 Cr | 5.32 Cr | 8.49 Cr | 3.17 Cr | 0.00 Cr | 5.32 Cr |
| 2023-09-30 | 90.68 Cr | 3.72 Cr | 0.00 Cr | 0.00 Cr | 3.72 Cr | 3.17 Cr | -0.55 Cr | 0.00 Cr | 3.72 Cr |
| 2023-06-30 | 44.38 Cr | 3.66 Cr | 0.00 Cr | 0.00 Cr | 3.66 Cr | 5.54 Cr | 1.88 Cr | 0.00 Cr | 3.66 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| 2013-09-27 | September 27, 13 | 2:1 |
| 2006-09-26 | September 26, 06 | 5:1 |
| 2004-03-25 | March 25, 04 | 2:1 |
| 2003-12-10 | December 10, 03 | 1083:1000 |
| 1999-07-26 | July 26, 99 | 10:1 |
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,558.65 | ₹3,739,637,772,000.00 | ₹781,719.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹5,506.25 | ₹1,461,738,681,250.00 | ₹64,908.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹2,949.60 | ₹998,277,372,000.00 | ₹166,276.00 |
| Mankind Pharma Limited | MANKIND | ₹2,291.25 | ₹945,320,533,950.00 | ₹177,711.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,114.75 | ₹928,700,476,795.00 | ₹434,095.00 |
| Lupin Limited | LUPIN | ₹1,934.60 | ₹883,108,142,600.00 | ₹259,741.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹870.20 | ₹875,621,346,000.00 | ₹343,556.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,050.85 | ₹610,335,781,700.00 | ₹413,280.00 |
| Alkem Laboratories Limited | ALKEM | ₹4,591.20 | ₹548,946,828,000.00 | ₹17,608.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹1,313.55 | ₹370,668,047,400.00 | ₹97,865.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,339.40 | ₹339,811,137,600.00 | ₹56,310.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,451.70 | ₹306,246,750,400.00 | ₹61,223.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,161.90 | ₹295,779,073,500.00 | ₹165,600.00 |
| Laurus Labs Limited | LAURUSLABS | ₹541.60 | ₹292,059,424,800.00 | ₹1,255,902.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,614.85 | ₹251,280,349,100.00 | ₹29,467.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,238.20 | ₹201,165,401,200.00 | ₹280,998.00 |
| Piramal Enterprises Limited | PEL | ₹877.00 | ₹197,744,206,000.00 | ₹172,994.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹7,180.00 | ₹179,500,000,000.00 | ₹18,235.00 |
| Eris Lifesciences Limited | ERIS | ₹1,181.00 | ₹160,768,349,000.00 | ₹22,410.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹775.65 | ₹152,464,090,950.00 | ₹312,147.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹917.85 | ₹146,196,065,850.00 | ₹70,165.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹11,307.10 | ₹145,068,962,290.00 | ₹40,103.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹801.90 | ₹143,628,309,000.00 | ₹553,341.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹1,794.05 | ₹136,368,790,385.00 | ₹351,707.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Granules India Limited | GRANULES | ₹474.45 | ₹115,051,278,300.00 | ₹761,172.00 |
| Procter & Gamble Health Limited | PGHL | ₹5,120.00 | ₹84,988,928,000.00 | ₹2,119.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹733.60 | ₹66,483,240,936.00 | ₹180,483.00 |
| FDC Limited | FDC | ₹380.40 | ₹61,932,924,000.00 | ₹76,550.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹623.30 | ₹60,953,067,970.00 | ₹158,952.00 |
| Strides Pharma Science Limited | STAR | ₹606.80 | ₹55,924,326,360.00 | ₹175,466.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹912.85 | ₹46,298,930,435.00 | ₹61,199.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹630.35 | ₹44,380,296,030.00 | ₹15,929.00 |
| Hikal Limited | HIKAL | ₹353.10 | ₹43,537,583,100.00 | ₹104,019.00 |
| Innova Captab Limited | INNOVACAP | ₹676.60 | ₹38,718,387,638.00 | ₹65,536.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹117.03 | ₹37,978,809,660.00 | ₹840,880.00 |
| Sequent Scientific Limited | SEQUENT | ₹145.38 | ₹36,388,904,760.00 | ₹484,563.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹2,080.00 | ₹34,401,120,000.00 | ₹13,355.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹316.20 | ₹31,707,903,600.00 | ₹60,257.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹346.80 | ₹31,652,436,000.00 | ₹50,219.00 |
| Suven Life Sciences Limited | SUVEN | ₹116.15 | ₹25,329,295,100.00 | ₹387,876.00 |
| Morepen Laboratories Limited | MOREPENLAB | ₹45.64 | ₹25,008,620,560.00 | ₹2,413,022.00 |
| Solara Active Pharma Sciences Limited | SOLARA | ₹469.75 | ₹23,648,166,244.00 | ₹100,544.00 |
| Alembic Limited | ALEMBICLTD | ₹89.77 | ₹23,051,320,050.00 | ₹318,318.00 |
| Indoco Remedies Limited | INDOCO | ₹226.93 | ₹20,933,815,947.00 | ₹228,598.00 |
| Bajaj HealthCare Limited | BAJAJHCARE | ₹635.05 | ₹20,056,974,665.00 | ₹289,638.00 |
Key Executives
Company Secretary & Compliance Officer
Mr. Kevalkumar Bharatkumar Thakkar
Gender: male
Year Born:
President of Real Estate Operations
Mr. Avaneesh Nath Sharma
Gender: male
Year Born:
MD, Chief Executive Officer & Executive Director
Ms. Malika Chirayu Amin
Gender: female
Year Born: 1955
Chief Financial Officer
Mr. Rasesh Shah
Gender: male
Year Born:
Associate Vice President of HR
Mr. Ambarish Jambhorkar
Gender: male
Year Born:
FAQs about Alembic Limited
Who is the CEO of the company?
The CEO is Ms. Malika Chirayu Amin.
What is the current market price of the stock?
The current price is ₹89.51.
What is the 52-week price range?
The range is ₹78.1-169.
What is the market capitalization of the company?
The market capitalization is ₹2,298.46 crores.
What is the dividend yield?
The dividend yield is 2.68%.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 7.30.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Alembic Limited (ISIN: INE426A01027) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹2,298.46 crores and an average daily volume of 594,447 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹2.4.